Pekkip Oncology Alliance AG

02/12/2021

02/12/2021

02/12/2021

Key takeaways for FUBIS!
De-risked proof of concept in humans (Phase 1) by using known compounds for this new duplex drug. Animal tests in fact show substantially less side effects than the compounds alone, postulating a very favorable risk profile.
First bisphosphonate duplex drug that is actually stable in-vivo and shows satisfactory efficacy of the conjugated compounds.
First bisphosphonate duplex drug with no negative effect on osteoblast, allowing bone formation while treating the metastases.
The duplex drug Linker is a unique and patented technology, more duplex drugs based on bisphosphonates and chemotherapy agents can be developed.
Ex*****on of clinical program is prepared; we have a standing collaboration contract with the University of Heidelberg that allows access to resources and leading facilities like the NCT.

02/12/2021

License to the Linker Technology.
The patent covers the full range of conjugates between bisphosphonates and any other compound linked.

02/12/2021

PEKKIP Oncology Alliance holds an exclusive, worldwide license to the Linker Technology and resulting molecules:

All of Prof. Dr. Schott‘s rights in patents or patent applications deriving from or being based upon PCT/EP2011/063326
Prof. Dr. Schott‘s secret technical and scientific knowledge relating to the invention (Contract Know-How)

02/12/2021

Key Metrics for Commercial Scenarios

02/12/2021

Roadmap for FUBIS Development

02/12/2021

Our Research Activity for FUBIS

02/12/2021

The competition has not found the right balance between risk profile and efficacy

02/12/2021

Our Linker Technology is the crucial element to bring together desired characteristics

02/12/2021

Pre-clinical tests find FUBIS safe, well-tolerated and effective against Bone Metastases

02/12/2021

FUBIS – Targeted Inhibition of Bone Resorption and Reduction of Tumor Size

02/12/2021

https://fubis-oncology.com/

02/12/2021

FUBIS – Targeted Inhibition of Bone Resorption and Reduction of Tumor Size!
FUBIS is a novel drug
for targeted treatment of bone metastases and has shown promising results in pre-clinical settings
Further development
of FUBIS is on the way, aiming to market this novel drug rapidly so that millions of patients may hopefully benefit from it soon
FUBIS offers an improved
side effect profile allowing for longer and safer treatment, a significant efficacy against osteoclasts and bone metastases in animal models. We expect that FUBIS will level-up specificity and safety for the treatment of bone metastases in clinical trials
PEKKIP Oncology Alliance
has led the development of FUBIS, in a close partnership with the University of Heidelberg and with the National Center for Tumor Diseases (NCT).